このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide (SEMA SMA)

Alleviating Carbohydrate Counting Using Weekly Subcutaneous Semaglutide Injections in People With Type 1 Diabetes on Closed-Loop Insulin Therapy: a 2x4 Factorial Randomized Placebo-Controlled Trial

A closed-loop insulin system, often labelled the "artificial pancreas" (AP), consists of an insulin pump, a continuous glucose monitor, and an interface coordinating between them to regulate insulin dosage based on glucose levels. Primarily designed for managing type 1 diabetes, this system has demonstrated significant benefits in previous studies. Yet, despite these advantages, certain challenges persist.

Semaglutide, utilized in treating type 2 diabetes and obesity, is a once-weekly injectable medication that elevates levels of a gastrointestinal hormone known as Glucagon-Like Peptide-1 (GLP-1). This hormone alters gastric emptying, inhibits glucagon release, and reduces appetite. While not officially sanctioned for type 1 diabetes treatment in North America, studies have explored its efficacy as an adjunctive therapy alongside insulin, yielding favorable outcomes in blood glucose regulation. Comparable drugs like liraglutide and exenatide have been employed in type 1 diabetes treatment as well, albeit with less pronounced glucose-regulating effects compared to semaglutide, even in type 2 diabetes.

The goal of this 50-week randomized placebo-controlled crossover 2x4 factorial designed trial is to assess whether commercial automated insulin delivery (AID) systems using rapid-acting insulin with adjunct weekly injections of semaglutide (at the maximally tolerated dose) can replace carbohydrate counting with simple meal announcements (SMA) without degrading glucose control.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

The main questions this study aims to answer are:

  • Can weekly injections of semaglutide at the maximum tolerated dose in individuals with T1D on closed-loop therapy with SMA and rapid-acting insulin result in a non-inferior time spent in target range (3.9-10 mmol/L) compared to weekly placebo injections on closed-loop system with full carbohydrate counting.

  • Can weekly injections of semaglutide at the maximum tolerated dose, in combination with ultra-rapid actin insulin (Lyumjev);

    1. Eliminate carbohydrate counting and any meal announcement (i.e fully closed-loop) in people with T1D on closed-loop therapy without degrading glucose control.
    2. Be more effective in substituting carbohydrate counting with SMA in people with T1D on closed-loop therapy compared with traditional rapid-acting insulin.

Participants will be asked to undergo two subsequent blinded drug interventions; one with semaglutide and the other with placebo. Both interventions include 4 meal strategies each with a 3-week duration; full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev.

研究の種類

介入

入学 (推定)

33

段階

  • フェーズ2
  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Quebec
      • Montreal、Quebec、カナダ、H4A 3J1
        • 募集
        • Research Institute of the McGill University Health Centre
        • 主任研究者:
          • Michael Tsoukas, MD
        • 副調査官:
          • Ahmad Haidar, Ph.D
        • 副調査官:
          • Vanessa Tardio, MD
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. At least 18 years of age
  2. A clinical diagnosis of T1D for at least one year, as per their treating diabetes physician in agreement with the primary investigator's clinical judgment (confirmatory C-peptide and antibodies will not be required)
  3. Minimum 3-month use of a commercial advanced automated insulin delivery system. 4.4. Agreement to use an effective method of birth control for individuals with child-bearing potential. Child-bearing potential refers to participants of the female sex post-menarche who have not reached menopause and who do not have a medical condition causing sterility (e.g., hysterectomy). Post-menopausal state refers to the absence of menses for 12 months without any alternative cause.

Exclusion Criteria:

  1. Use of GLP1-RAs within the last 4 weeks.
  2. Use of any anti-hyperglycemic agent other than insulin within the last 2 weeks.
  3. Planned or ongoing pregnancy
  4. Breastfeeding
  5. Severe hypoglycemic episode within the last 3 months, defined as an event where glucose was < 4 mmol/L resulting in seizure, loss of consciousness, or need to present to the emergency department
  6. Severe diabetic ketoacidosis (DKA) within the last 6 months ("severe" referring to need to present to medical attention and requirement of intravenous insulin)
  7. Prior history of acute pancreatitis, chronic pancreatitis, or gallbladder disease
  8. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
  9. Severe impairment of renal function with eGFR <30 mL/min/1.73 m2 (using CKD-EPI formula), measured within the last 12 months
  10. Clinically significant diabetic retinopathy or gastroparesis, as per the clinical judgment of the investigator
  11. Bariatric surgery within the last 6 months.
  12. A serious medical or psychiatric illness that is likely to interfere with study participation as per the judgment of the investigator (e.g. cirrhosis, active cancer, decompensated schizophrenia).
  13. Body mass index ≤ 21 kg/m2
  14. Inability or unwillingness to comply to safe diabetes management in the view of the study group (e.g. inappropriate treatment of hypoglycemia or lack thereof)
  15. Concern for safety of the participant, as per the clinical judgment of the primary investigator

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:定期的な閉ループインスリンポンプ療法における毎週のプラセボ注射

The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.

実験的:Weekly semaglutide (Ozempic®) injections on regular closed-loop insulin pump therapy

Semaglutide is a Glucagon-like peptide 1 (GLP-1) receptor agonist. It up regulates GLP-1, which reduces glucagon levels, increases satiety and - in some particular cases - increases insulin production. It will be subcutaneously injected weekly by participants at progressively increasing doses. Once the maximum tolerated dose is achieved, participants will begin the meal strategies.

The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of daytime plasma glucose levels spent in target range (semaglutide vs. placebo)
時間枠:24 weeks

Target range is defined to be between 3.9 and 10.0 mmol/L of plasma glucose for placebo vs semaglutide (at maximal tolerated dose) on closed-loop insulin therapy

24 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Percentage of time spent in the range of glucose levels between 3.9 and 7.8 mmol/L
時間枠:24 weeks

% as per CGM data

24 weeks
Percentage of time spent in glucose levels below 3.9 and 3.0 mmol/L
時間枠:24 weeks

% as per CGM data

24 weeks
Percentage of time spent in glucose levels above 7.8, 10 and 13.9 mmol/L
時間枠:24 weeks

% as per CGM data

24 weeks
Mean glucose level
時間枠:24 weeks

Defined as per CGM data, in mmol/L

24 weeks
Standard deviation of glucose levels as a measure of glucose variability
時間枠:24 weeks

Defined as per CGM data, in mmol/L

24 weeks
Percentage coefficient of variation of glucose levels
時間枠:24 weeks

% as per CGM data

24 weeks
Proportions of participants with time in range between 3.9 - 10.0 mmol/L≥ 70%
時間枠:24 weeks

As per CGM data

24 weeks
Glycated hemoglobin (HbA1c)
時間枠:24 weeks

Blood test to assess glucose control within 3-4 months

24 weeks
Area under the curve 0-2h post meal, 0-3h post peal
時間枠:24 weeks

As per CGM data

24 weeks
Average scores between interventions on the Type 1 Diabetes Distress Scale questionnaire
時間枠:24 weeks

17-item questionnaire with a 6-point Likert scale from 1 (no stress) to 6 (high stress) for each item. Total score obtained from summing the scores of all items

24 weeks
Average scores between interventions on the Diabetes Treatment Satisfaction questionnaire
時間枠:24 weeks

8-item questionnaire with a 7-point Likert scale ranging from 0 (low satisfaction) to 6 (high satisfaction). Total score obtained from summing the scores of all items.

24 weeks
Average scores between interventions based on the Hypoglycemic Fear Survey - II
時間枠:24 weeks

33-item questionnaire with a 5-point Likert scale ranging from 1 (never) to 5 (almost always). Total score obtained from summing the scores of all items.

24 weeks
Heart rate
時間枠:24 weeks

Beats per minute

24 weeks
Blood pressure
時間枠:24 weeks

mmHg

24 weeks
Measure of body weight
時間枠:24 weeks

Measurements done at visit - weight in kilograms

24 weeks
Measure of body mass index
時間枠:24 weeks

Measurements done at visit - body mass index as per kg/m^2

24 weeks
Measure of waist circumference and hip circumference
時間枠:24 weeks

Measurements done at visit - circumference in cm

24 weeks
Measure of waist-to-hip ratio
時間枠:24 weeks

Measurements done at visit

24 weeks
Lipid profile, specifically: LDL-cholesterol, HDL-cholesterol, triglycerides
時間枠:24 weeks

Blood tests, in mmol/L

24 weeks
Urine albumin-creatinine ratio
時間枠:24 weeks

Urine test

24 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年12月1日

一次修了 (推定)

2027年12月1日

研究の完了 (推定)

2027年12月1日

試験登録日

最初に提出

2024年4月18日

QC基準を満たした最初の提出物

2024年4月23日

最初の投稿 (実際)

2024年4月26日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月19日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2024-10227

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The raw data (that is, insulin delivery, glucose levels and individual participant data) and informed consent form will be shared by the corresponding author, for academic purposes, subject to a material transfer agreement and approval of the McGill University Health Center's Research Ethics Board. All data shared will be de-identified. Raw data will be shared for non-commercial use upon reasonable request and a material transfer agreement.

IPD 共有サポート情報タイプ

  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。